ArticleRenal failure2026
Salivary decorin as a potential noninvasive biomarker in chronic kidney disease: a comparative study with serum levels.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is characterized by progressive renal fibrosis and irreversible loss of kidney function. Decorin, an extracellular matrix proteoglycan with antifibrotic properties, may reflect underlying fibrotic activity and has emerged as a potential biomarker. However, its role in noninvasive biological fluids such as saliva remains unclear. In this cross-sectional study, 88 patients with CKD stages 3-5 and 30 healthy controls were included. Serum and unstimulated saliva samples were collected simultaneously, and decorin levels were measured using enzyme-linked immunosorbent assay (ELISA). Group comparisons were performed using non-parametric tests, and correlations were analyzed using Spearman's method. Serum decorin levels showed an increasing trend with advancing CKD stage; however, these differences did not reach statistical significance and were not correlated with renal function parameters. In contrast, salivary decorin levels were significantly lower in CKD patients compared to controls and demonstrated a numerical decrease across CKD stages. No significant correlation was observed between serum and salivary decorin levels. Salivary decorin may represent a potential noninvasive candidate marker in CKD; however, further large-scale longitudinal studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.